Compare EPAM Systems Inc (EPAM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Zimmer Biomet Holdings Inc — how do they compare? EPAM Systems Inc trades at $113.92 (market cap $5.87B), while Zimmer Biomet Holdings Inc trades at $89.01 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.9× EPAM Systems Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EPAM | ZBH | |
|---|---|---|
Market Cap | $5.87B | $16.95B |
Volume | 847,420 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $221.40 | $103.98 |
52-Week Low | $76.04 | $79.58 |
Typical Hold Time | 37 Days | 89 Days |
Enterprise Value | $5.24B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $114.00, up 5.24% today, with a bearish technical signal but strong fundamentals. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $3.38 surpassing the $3.16 expectation. Revenue grew to $5.46 billion in 2025, though net income margin compressed to 6.92%. The company maintains solid cash flow from operations of $654.93 million and a healthy balance sheet with $1.29 billion in cash.
The outlook is mixed; analyst consensus is a Buy with a $119.00 price target, but near-term revenue headwinds and AI disruption risks persist. Investment opportunity lies in attractive valuation multiples (P/E 15.45, EV/EBITDA 7.25) and potential share repurchases urged by activists. Key risks include slower North American growth and competitive pressures in digital transformation services.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
